XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information
Note 14 — Segment Information

Abbott’s principal business is the discovery, development, manufacture, and sale of a broad line of healthcare products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, healthcare facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care businesses are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. The chief operating decision maker (CODM) at Abbott is the Chief Executive Officer (CEO). The CODM primarily considers sales and operating margin to assess the performance of segments and to allocate resources, where segment operating margin profitability includes cost of products sold and operating expenses. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General and AdministrativeOperating Earnings
Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,Three Months Ended June 30,
(in millions)2025202420252024202520242025202420252024
Established Pharmaceuticals$1,383 $1,294 $(631)$(591)$(43)$(44)$(363)$(344)$346 $315 
Nutritionals2,212 2,150 (1,155)(1,148)(54)(53)(585)(576)418 373 
Diagnostics 2,173 2,195 (1,224)(1,203)(154)(162)(423)(400)372 430 
Medical Devices 5,369 4,734 (1,758)(1,627)(430)(379)(1,385)(1,221)1,796 1,507 
Total$11,137 $10,373 $(4,768)$(4,569)$(681)$(638)$(2,756)$(2,541)$2,932 $2,625 
Other5 4 
Net sales$11,142 $10,377 
Corporate functions and plan benefit costs(65)(80)
Net interest expense(50)(58)
Share-based compensation (a)(142)(141)
Amortization of Intangible assets(420)(471)
Other, net (b)(105)(268)
Earnings before Taxes$2,150 $1,607 

Net Sales to External CustomersCost of Products SoldResearch and DevelopmentSelling, General and AdministrativeOperating Earnings
Six Months Ended
 June 30,		Six Months Ended
 June 30,		Six Months Ended
 June 30,		Six Months Ended
 June 30,		Six Months Ended
 June 30,
(in millions)2025202420252024202520242025202420252024
Established Pharmaceuticals$2,643 $2,520 $(1,200)$(1,175)$(85)$(85)$(714)$(678)$644 $582 
Nutritionals4,358 4,218 (2,279)(2,236)(106)(105)(1,161)(1,127)812 750 
Diagnostics 4,227 4,409 (2,376)(2,391)(305)(317)(815)(797)731 904 
Medical Devices 10,264 9,187 (3,356)(3,174)(831)(747)(2,672)(2,399)3,405 2,867 
Total$21,492 $20,334 $(9,211)$(8,976)$(1,327)$(1,254)$(5,362)$(5,001)$5,592 $5,103 
Other8 7 
Net sales$21,500 $20,341 
Corporate functions and plan benefit costs(93)(146)
Net interest expense(99)(119)
Share-based compensation (a)(431)(445)
Amortization of Intangible assets(840)(943)
Other, net (b)(201)(407)
Earnings before Taxes$3,928 $3,043 
______________________________________
(a)
Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b)
Other, net for the three and six months ended June 30, 2025 and 2024 includes charges related to restructurings, fair value adjustments to contingent consideration and integration costs related to business combinations. Other, net for the six months ended June 30, 2025 and 2024 also includes impairment charges related to various investments. Other, net for the three and six months ended June 30, 2024 also includes charges related to the impairment of IPR&D assets, as well as a loss on the divestiture of a non-core business.
DepreciationAdditions to
Property and Equipment
Three Months Ended June 30,Three Months Ended June 30,
(in millions)2025202420252024
Established Pharmaceuticals$25 $24 $39 $37 
Nutritionals44 39 81 103 
Diagnostics135 129 166 169 
Medical Devices94 87 145 158 
Total Reportable Segments298 279 431 467 
Other59 55 62 68 
Total$357 $334 $493 $535 

DepreciationAdditions to
Property and Equipment
Six Months Ended June 30,Six Months Ended June 30,
(in millions)2025202420252024
Established Pharmaceuticals$48 $48 $72 $66 
Nutritionals86 78 160 176 
Diagnostics261 258 301 292 
Medical Devices182 174 301 293 
Total Reportable Segments577 558 834 827 
Other116 109 122 117 
Total$693 $667 $956 $944 


Total Assets
As of June 30,As of December 31,
(in millions)20252024
Established Pharmaceuticals$3,732 $3,087 
Nutritionals4,910 4,404 
Diagnostics8,177 7,678 
Medical Devices10,555 9,472 
Total Reportable Segment Assets$27,374 $24,641 
Cash and investments8,240 8,853 
Goodwill and intangible assets29,872 29,755 
All other (c)18,513 18,165 
Total Assets$83,999 $81,414 
(c)As of June 30, 2025 and December 31, 2024, all other includes the long-term assets associated with the defined benefit plans and certain deferred tax assets.